Compare Altria Group Inc (MO) vs GeneDx Holdings Corp (WGS) Price & Performance

Altria Group IncTrade

GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Altria Group Inc vs GeneDx Holdings Corp — how do they compare? Altria Group Inc trades at $65.04 (market cap $108.58B), while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: Altria Group Inc is far larger — about 44.5× GeneDx Holdings Corp's market cap, and Altria Group Inc pays a 6.52% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

	MO	WGS
Market Cap	$108.58B	$2.44B
Sector	Consumer Staples	Technology
52-Week High	$74.92	$167.51
52-Week Low	$54.72	$34.51
Enterprise Value	$130.79B	$2.48B
Dividend Yield	6.52%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

Invesco's PEY ETF outperforms with a dividend-growth filter, offering higher returns and reliable income.24/7 Wall Street · 19 hours agoBullish Altria offers 6.3% yield with 60 years of dividend growth, trading at a low valuation amid regulatory risks.Seeking Alpha · 4 days agoBullish View details →

WGS

View details →

About Altria Group Inc

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.